Presented Abstracts Based on
NCDR® Registries
PRESENTED ABSTRACTS

Table of Contents

<table>
<thead>
<tr>
<th>Registry Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFIB ABLATION REGISTRY™</td>
<td>3</td>
</tr>
<tr>
<td>CATHPCI REGISTRY®</td>
<td>4</td>
</tr>
<tr>
<td>CARE REGISTRY®</td>
<td>16</td>
</tr>
<tr>
<td>CHEST PAIN - MI REGISTRY™</td>
<td>18</td>
</tr>
<tr>
<td>DIABETES COLLABORATIVE REGISTRY®</td>
<td>24</td>
</tr>
<tr>
<td>EP DEVICE IMPLANT REGISTRY™ (FORMERLY ICD)</td>
<td>25</td>
</tr>
<tr>
<td>IMPACT REGISTRY®</td>
<td>30</td>
</tr>
<tr>
<td>LAAO REGISTRY™</td>
<td>32</td>
</tr>
<tr>
<td>PINNACLE REGISTRY®</td>
<td>33</td>
</tr>
<tr>
<td>PVI REGISTRY™</td>
<td>38</td>
</tr>
<tr>
<td>STS/ACC TVT REGISTRY™</td>
<td>39</td>
</tr>
</tbody>
</table>

2. **419**: Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. J. Rymer. ACC 2018. Poster Presentation.


7. **156**: Costs Associated with Trans radial Primary PCI among Elderly Patients with STEMI in the Medicare Fee-For-Service Beneficiaries. A. Amin. ACC 2017.


February 2022


29. **172**: Length of Hospital Stay and Associated Clinical Outcomes in Elderly Patients Following Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: A Report from the National Cardiovascular Data Registry®. R. Swaminathan. ACC 2014. Poster Presentation.


34. **243B**: Performance of hospitals on PCI metrics and correlation with 30-day re-admissions. P. Chui. AHA 2014. Oral Presentation.


February 2022

39. 156: Trans radial PCI is associated with lower cost in Medicare Fee-for-Service Beneficiaries following elective PCI. A. Amin. ACC 2013. Oral Presentation.


42. 158B: Predicting Target-Vessel Revascularization among Older Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent Era. C. Hess. ACC 2013. Poster Presentation.

43. 159: Gaps in referral to cardiac rehabilitation after percutaneous coronary intervention in the United States: insights from the National Cardiovascular Data Registry. K. Aragam. ACC 2013. Poster Presentation.

44. 161: Large Variation in Contrast Use during PCI – An Important Opportunity for Improving Contrast-induced acute kidney injury Outcomes. A. Amin. QCOR 2013. Poster Presentation.

45. 167: Trans radial PCI is associated with lower readmission rates for Medicare fee-for-service beneficiaries following elective PCI. M. Patterson. ACC 2013. Poster Presentation.


53. 122: Are “All-Comer” Clinical Trials Representative of Contemporary Clinical Practice: A Linked Analysis of the Dual Antiplatelet Therapy (DAPT) Study and the National Cardiovascular Data Registry. R. Yeh. AHA 2013. Poster Presentation.


February 2022

60. **54A**: Association between Use of Anti-Anginal Medications for Stable Coronary Disease and Rates of Percutaneous Coronary Intervention. W. Borden. **ACC 2012. Poster Presentation.**

61. **111**: Practice Comparisons Between Japan and the United States - Early Results with Japanese Percutaneous Coronary Intervention Registry and Its Direct Comparison with the Cath/PCI Registry”. S. Kohsaka. **ACC 2012. Poster Presentation.**


63. **117**: Gender Differences in the Use and Effectiveness of Bleeding Avoidance Strategies Following PCI. S. Daugherty. **ACC 2012. Oral Presentation.**

64. **119**: Impact of Reduced Door to Balloon Times on Mortality in Patients Undergoing Primary PCI in the United States. D. Menees. **ACC 2012. Poster Presentation.**

65. **123**: Non-System Reasons for Delay in Door-To-Balloon Time and Associated In-hospital Mortality Outcomes. R. Swaminathan. **ACC 2012. Poster Presentation.**


73. **142**: Do Interventional Cardiology Training Programs Have Worse Outcomes Early in the Academic Year? An Assessment of the “July Effect” from the National Cardiovascular Database Registry. B. Hawkins. **AHA 2012. Oral Presentation.**

74. **144**: Patient Selection for Bare Metal Stent Placement and Associated Longitudinal Outcomes Before and After the FDA Drug Eluting Stent Advisory. R. Harrison. **AHA 2012. Oral Presentation.**


76. **N/A**: A Hospital Outcome Prediction Model in Percutaneous Coronary Intervention: Volume-Specific Analysis Based on Adverse Ratios and Risk Adjusted Mortality. J. Wei. **AHA 2012. Poster Presentation.**

77. **88**: Patterns and Predictors of Stress Testing Modality after Percutaneous Coronary Intervention: Retrospective Analysis using the NCDR®. J. Federspiel. **QCOR 2012. Poster Presentation.**


80. **126B**: Hospital PCI Appropriateness and In-Hospital Procedural Outcomes: Insights from the NCDR®. S. Bradley. **QCOR 2012. Poster Presentation Winner: Young Investigator Award.**
February 2022


86. 100: Left-Dominant Coronary Artery Circulation is Associated with Higher In-Hospital Mortality Among Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndrome: Data from the American College of Cardiology National Cardiovascular Data Registry for Catheterization Percutaneous Coronary Intervention. S. Parikh. ACC 2011. Oral Presentation.


91. 110B: Hospital Variation in Bleeding Complications Following Percutaneous Coronary Intervention (PCI): Results from the National Cardiovascular Data Registry (NCDR). E. Peterson. AHA 2011. Oral Presentation.


98. 8: Clinical Strategies and Bleeding Outcomes in Elderly Patients Undergoing Primary PCI: Results from the NCDR CathPCI Registry. J. Dodson. QCOR 2011. Poster Presentation.


104. **91A**: Comparative Effectiveness of Bleeding Avoidance Therapies in PCI Patients: Analysis from the National Cardiovascular Data Registry. S. Marso. ACC i2 2010. Poster Presentation.


106. **91C**: Comparative Effectiveness of Radial Access and Bivalirudin on PCI-Related Bleeding Events: Analysis from the National Cardiovascular Data Registry. S. Marso. ACC i2 2010. Poster Presentation.


111. **149**: Comparison of Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention for Previously Stented Versus De Novo Culprit Lesions: Insights from the National Cardiovascular Data Registry CathPCI Registry®. K. Stribling. TCT 2010. Poster Presentation.


113. **104**: Impact of Predicted Bleeding Risk on the Cost-Effectiveness of Direct Thrombin Inhibition vs. Heparin Monotherapy for Patients Undergoing PCI. A. Amin. QCOR 2010. Oral Presentation: Young Investigator Award.


February 2022

121. N/A: Annual case volume is not a strong predictor of bleeding complications after percutaneous coronary intervention: A report from the National Cardiovascular Data Registry. S. Rao. ACC 2009. Poster Presentation.


126. 90B: Renally Cleared Anti-Thrombotic Agents Among Dialysis Patients Receiving Percutaneous Coronary Interventions: Insights From the ACC-NCDR Cath-PCI Registry. T. Tsai. AHA 2009. Oral Presentation: Finalist for Young Investigator Award [YIA].


128. 15: Changing Guidelines May Affect Assessments of Quality of Care for Patients Undergoing PCI. G. Lin. ACC 2008.

129. 27A: Non-infarct Artery Intervention During Primary PCI for ST-segment elevation myocardial infarction May Be a Reasonable Strategy in Selected Hemodynamically Stable Patients: Results from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). M. Cavender. ACC 2008.

130. 27B: Prevalence and In-hospital Outcomes of Multi-vessel PCI during Primary PCI for ST-segment elevation myocardial infarction: Results from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). M. Cavender. ACC 2008.

131. 47: Clinical Characteristics and in Hospital Outcomes of Patients Undergoing Rescue Percutaneous Coronary Intervention Compared to Primary Percutaneous Intervention. S. Burjonroppa. ACC 2008.


135. 5: Interaction of Age and Glomerular Filtration Rate to Predict In-Hospital Mortality Following Percutaneous Coronary Intervention for Acute Myocardial Infarction. F. Cardarelli. AHA 2008.


139. 58: Do Hospitals that Improve “Walk In” Door-to-Balloon Times for Primary Percutaneous Coronary Intervention Also Improve “Transfer In” Door-to-Balloon Times? T. Wang. AHA 2008.

February 2022


142. **39**: Intermediate Volume Operators Attempt Percutaneous Coronary Intervention of Chronic Total Occlusions More Frequently Than Low- or High-Volume Operators: An Analysis from the American College of Cardiology-National Cardiovascular Data Registry Database of 45,826 CTO Patients. J. Grantham. **ACC 2007.**

143. **51**: Comparison of Hospital Door-to-Balloon Times Reported by CMS and ACC-NCDR: Apples and Oranges? B. Nallamothu. **ACC 2007.**

144. **N/A**: The Radial Approach to Percutaneous Coronary Intervention Is Associated with a Lower Risk for Complications Regardless of Radial Procedure Volume: A Report from the American College of Cardiology-National Cardiovascular Data Registry. S. Rao. **ACC 2007.**


146. **39**: Current Practice Patterns in Percutaneous Treatment of Total Chronic Occlusions and the Association of Operator Volume with Treatment. J. A. Grantham. **AHA 2007.**

147. **40**: The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National Cardiovascular Data Registry. A. Frutkin. **AHA 2007.**


149. **41B**: Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Predictive Model From 302,152 Patients in the ACC-NCDR. S. Mehta. **AHA 2007.**

150. **42**: Are we meeting the goals? Gender Analysis of Evidence Based Medical Therapies among patients presenting with an Acute Coronary Syndrome (ACS) who undergo Post-Percutaneous Coronary Intervention (PCI): Results from the ACC-NCDR Cath/PCI Registry. N. Akhter. **AHA 2007.**


152. **45**: Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). M. Singh. **AHA 2007.**

153. **46**: Characteristics and Outcomes of Patients Taking Warfarin Prior to Percutaneous Coronary Intervention. A. Aggarwal. **AHA 2007.**

154. **57A**: Young Women Undergoing Elective PCI Procedures Have Higher Complications Rates Than Similarly Aged Men: Results from the ACC-NCDR Registry. J. Lichtman. **AHA 2007.**

155. **57B**: Conventional Risk Factors Are Highest for Minority Women Presenting with Myocardial Infarction: Results from the ACC-NCDR Registry. J. Lichtman. **AHA 2007.**

156. **N/A**: Absence of Flow-Limiting Coronary Artery Disease Among Patients Undergoing Emergent Cardiac Catheterization for ST Segment Elevation Myocardial Infarction in the National Cardiovascular Data Registry CathPCI Registry: Implications for Primary Angioplasty Programs. K. Ho. **AHA 2007.**

157. **47**: Incidence and Predictors of Bleeding Among Patients Undergoing Rescue Percutaneous Coronary Intervention after Failed Fibrinolysis for ST-Elevation Myocardial Infarction. S. Burjonroopa. **TCT 2007.**

158. **N/A**: Relationship Between Hospital PCI Volume and In-Hospital Major Adverse Clinical Events: The ACC-NCDR Results. L. W. Klein. **ACC 2006.**

159. **N/A**: In-Hospital Outcomes in Patients with ACS Treated with Sirolimus and Paclitaxel Drug-Eluting Stents: Experience from the ACC-NCDR Database. E Veledar. **ACC 2006.**

160. **N/A**: A New Score Assessing Programmatic PCI Case Risk: The ACC-NCDR Complexity Score. L. W. Klein. **ACC 2006.**
February 2022

161. **2:** Time-to-Reperfusion in Patients Undergoing Inter-Hospital Transfer for Primary Percutaneous Intervention in the United States: Results from the National Cardiovascular Data Registry. B. K. Nallamothu. *AHA 2006.*


163. **6:** Effect of Insurance Status on Use of Drug-Eluting Stents versus Bare Metal Stents in Patients Undergoing Elective Percutaneous Coronary Intervention. R. Vicuna. *AHA 2006.*

164. **22:** Lower Procedural Success and Higher Complications in Octogenarians with STEMI Referred for Emergency Cardiac Catheterization: Results from the American College of Cardiology—National Cardiovascular Data Registry. J. P. Curtis. *AHA 2006.*

165. **N/A:** PCI in Asymptomatic Outpatients Undergoing Cardiac Catheterization: Results from the American College of Cardiology—National Cardiovascular Data Registry. J. P. Curtis. *AHA 2006.*

166. **N/A:** Post-Procedural Outcomes in Hispanics, Asians, American Indians, and Caucasians Following Percutaneous Coronary Intervention. A. D. Patel. *AHA 2006.*


168. **N/A:** Contemporary Analysis of the Association between Hospital Volume and In-Hospital Death in Patients Undergoing Percutaneous Coronary Intervention: Results from the National Cardiovascular Data Registry. B. K. Nallamothu. *AHA 2006.*

169. **N/A:** Renal Failure, In-Hospital Mortality and Unplanned Coronary Artery Bypass Grafting Among 85 Years and Older Percutaneous Coronary Intervention Patients with Non-ST Elevation and ST Elevation Myocardial Infarction: Experience from the American College of Cardiology—National Cardiovascular Data Registry. E. Veledar. *American Society of Nephrology 2006.*

170. **11B:** Demographic Variations in Percutaneous and Surgical Revascularization of Unprotected Left Main Coronary Artery Stenosis: A Report from the American College of Cardiology—National Cardiovascular Data Registry. H. W. Huang. *CRT 2006.*

171. **N/A:** Patterns of Clopidogrel Use in Patients Undergoing Staged Percutaneous Coronary Intervention: A Report from the American College of Cardiology—National Cardiovascular Data Registry. A. J. Baumgarten. *CRT 2006.*


173. **N/A:** Comparison of In-Hospital Outcomes in Diabetics and Non-Diabetics Using the Paclitaxel and Sirolimus Drug-Eluting Stents: Results from the ACC-NCDR. E. Veledar. *CV Quality Forum 2006.*


177. **23:** Comparison of in-hospital mortality for PCI patients receiving DES comparing Sirolimus vs Paclitaxel with or without acute myocardial infarction (AMI); the American College of Cardiology National Cardiovascular Data Registry (ACC/NCDR) experience. W. Weintraub. *AHA 2005.*


179. **N/A:** On-site surgical backup as a predictor of mortality among PCI patients with STEMI, NSTEMI, or no AMI. J. K. Foster. *AHA 2005.*
February 2022

180.  N/A: Relationship between Hospital Coronary Angioplasty Volume and In-hospital Mortality: Results from The American College of Cardiology - National Cardiovascular Data Registry. Z. Zhang. AHA 2005.

181.  N/A: Outcome of Patients 85 and Older Undergoing PCI for Chronic CAD, Non-ST elevation and ST elevation MI: Experience from the American College of Cardiology National Cardiovascular Data Registry. E. Veleidar. AHA 2005.


184.  N/A: Severity of Coronary Disease in End-Stage Renal Disease Patients: Angiography Results from the American College of Cardiology - National Cardiovascular Data Registry. C. Jurkovitz. American Society of Nephrology 2005.


187.  N/A: Racial outcomes of lesion characteristics and coronary stent use on lesion success - observations from the American College of Cardiology - National Cardiovascular Data Registry. A.D. Patel. Society for Cardiovascular Angiography and Interventions 2005.


190.  N/A: Risk adjusted modeling of in hospital mortality for insulin-dependent PCI patients receiving drug eluting stents; Experience from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). E. Veleidar. Transcatheter Cardiovascular Therapeutics 2005.


February 2022


200. **N/A:** Have recommendations for cholesterol-lowering therapy been effectively implemented in patients presenting for percutaneous coronary intervention with prior revascularization? A report from the ACC-NCDR. M. Levy. TCT 2004.

201. **N/A:** Effect of Gender According to Age on In-Hospital Mortality in Patients with Acute Myocardial Infarction in the ACC-NCDR. S. C. Beinart. ACC 2003.

202. **N/A:** Predictors of In-Hospital Outcomes of Percutaneous Coronary Intervention in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (UA/NSTEMI): A Report from the National Cardiovascular Data Registry. L. W. Klein. TCT 2003.

203. **N/A:** The Expected Rate of Normal Coronary Arteriograms in the Cardiac Laboratory. B. D. McCallister. ACC 2002.

204. **N/A:** Mortality After Emergent PCI in Cardiogenic Shock Secondary to Acute Myocardial Infarction and Usefulness of a Mortality Prediction Model. L. W. Klein. ACC 2002.

205. **N/A:** Emergency CABG after Failed PCI in Contemporary Practice: A Report from the ACC-NCDR. M. A. Kutcher. ACC 2002.

206. **N/A:** Gender Differences in Frequencies of Significant and Severe Coronary Disease in the ACC-NCDR. L. J. Shaw. ACC 2002.

207. **N/A:** Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in Severe Coronary Artery Disease—Does Contemporary Practice Reflect Existing American College of Cardiology American Heart Association Guidelines? R. Gibbons. AHA 2002.

208. **N/A:** Effect of Hospital Volume on PCI Outcomes in the ACC-NCDR. S. C. Beinart. AHA 2002.

209. **N/A:** Relationship of Coronary Stenting and Glycoprotein IIb/IIIa Inhibitors to PCI Outcomes in Insulin-Dependent Diabetics: A Report from the American College of Cardiology—National Cardiovascular Data Registry. L. W. Klein. AHA 2002.

210. **N/A:** Predictors of Outcome of Primary PCI in ST Elevation Myocardial Infarction in 6,521 Consecutive Cases During 2001: A Report from the American College of Cardiology—National Cardiovascular Data Registry. L. W. Klein. AHA 2002.

211. **N/A:** Intervention in Saphenous Vein Grafts: A Predictive Model of Mortality Based on Clinical Presentation of 5,899 Consecutive Cases in the ACC-NCDR. L. W. Klein. AHA 2002.


213. **N/A:** Relationship of Coronary Stenting and Glycoprotein IIb/IIIa Inhibitors to PCI Outcomes in Insulin-Dependent Diabetics: A Report from the American College of Cardiology—National Cardiovascular Data Registry. R. G. Brindis. CV Quality Forum 2002.

214. **N/A:** Effect of Hospital Volume on PCI Outcomes in the ACC-NCDR. S. C. Beinart. CV Quality Forum 2002.

215. **N/A:** Hospital Variability in Diagnostic Catheterization: Insights from the ACC-NCDR. M. Radford. CV Quality Forum 2002.

216. **N/A:** The Influence of Diabetes on the In-Hospital Outcome of PCI in the ACC-NCDR. L. W. Klein. ACC 2001.

217. **N/A:** Are Women at Increased Risk of Death after PCI? Results from the ACC-NCDR Database. H. V. Anderson. ACC 2001.

218. **N/A:** Outcomes of PCI in Octogenarian Patients Who Present with Acute MI. L. W. Klein. AHA 2001.
February 2022

219. **N/A**: Clinical Risk Score to Predict the Likelihood of LM or 3-Vessel CAD for Patients in the ACC-NCDR. R. Gibbons. *AHA 2001.*


221. **N/A**: Which is more important in measuring a PCI patient's risk of adverse outcomes, clinical state or lesion classification? R. J. Krone. *AHA 2001.*


223. **N/A**: NO - Quality is More Important than Quantity. H. V. Anderson. *TCT 2001.*


226. **N/A**: The Influence of Age on the In-Hospital Outcome of PCI: Results from the ACC-NCDR. H. V. Anderson. *AHA 2000.*


228. **N/A**: Complications of Percutaneous Coronary Interventions: Preliminary Results from the ACC-NCDR. H. V. Anderson. *CV Quality Forum 2000.*


2. **5A**: Carotid Artery Stenting and Carotid Endarterectomy are Comparable Among Medicare Beneficiaries Treated in Routine Clinical Practice. J. Jalbert. AHA 2014. Poster Presentation.
16. **11A**: Carotid revascularization immediately prior to urgent cardiac surgery: Practice patterns associated with the choice of carotid artery stenting (CAS) or endarterectomy (CEA) from the NCDR-CARE registry. C. Don. ACC 2010. Poster Presentation.
17. **11B**: Carotid revascularization immediately prior to urgent cardiac surgery: Clinical outcomes associated with the choice of carotid artery stenting (CAS) or endarterectomy (CEA) from the NCDR-CARE registry. C. Don. ACC 2010. Poster Presentation.

February 2022

Chest Pain - MI Registry™


17. 133A: Contemporary Patterns of Ticagrelor use in Patients with Acute Myocardial Infarction: Insight from the National Cardiovascular Data Registry (NCDR). S. Basra. ACC 2016. Young Investigators Award. Moderated Poster Presentation.

19. **137**: Utilization, Characteristics, and In-Hospital Outcomes for Patients with ST-Elevation Myocardial Infarction Undergoing in Hospital Coronary Artery Bypass Grafting (CABG). Yi Pi. **ACC 2016. Poster Presentation.**


23. **133B**: Contemporary Patterns of Ticagrelor use in Patients with Acute Myocardial Infarction: Insight from the National Cardiovascular Data Registry (NCDR). S. Basra. **AHA QCOR 2016. Oral Presentation.**


27. **156**: Relationship between the CMS 30-day readmission rates for acute myocardial infarction patients and their quality of care and outcomes across NCDR-ACTION/GWTG participating centers. A. Pandey. **AHA 2016. Poster Presentation.**


29. **N/A**: Smoking Cessation medication use after acute MI. Padigipati. **AHA 2016. Poster Presentation.**


31. **158**: Hospital Performance on the NCDR ACTION Registry-GWTG “All-or-None Composite Measure. N. Desai. **ACC 2016. Oral Presentation.**

32. **82**: Post-Hospital Outcomes in Patients with Acute Myocardial Infarction Complicated by Shock: Findings from the ACTION Registry®-GWTGTM. R Shah. **ACC 2015. Poster Presentation.**

33. **83**: The Association of Left Ventricular Ejection Fraction with 1 Year Mortality after Myocardial Infarction: Findings from the ACTION Registry-GWTG Medicare Linked Database. N. Sutton. **ACC 2015. Poster Presentation.**


36. **180**: Socioeconomic Disparities in Acute Myocardial Infarction Hospital Care in the National Cardiovascular Data Registry. J. Udell. **ACC 2015. Oral Presentation.**

37. **69**: The Association of Electronic Health Record Use with Acute MI Quality of Care and Outcomes: Results from the NCDR®. J. Enriquez. **AHA 2014. Oral Presentation.**

February 2022


40. **73**: Effects of Pre-Hospital ECG Use and Patient Residence Distance from PCI Center on Time to Device Activation in ST Segment Elevation Myocardial Infarction: A Retrospective Analysis from the NCDR. B. Mumma. AHA 2014. Oral Presentation.


42. **75**: In-Hospital ADP Receptor Inhibitor Switching in Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry®. A. Bagai. AHA 2014. Oral Presentation.


46. **67**: Frequency and Impact of Prior Myocardial Infarction among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: Results from the NCDR®. L. Shen. ACC 2013. Poster Presentation.


49. **70**: Trends in Cardiac Rehabilitation Referral after Myocardial Infarction: Data from the National Cardiovascular Data Registry (NCDR®). A. Beatty. AHA QCOR 2013. Poster Presentation.


51. **50**: Association of Chronic Lung Disease with Treatments and Outcomes of Acute Coronary Syndromes: Results from the NCDR®. J. Enriquez. AHA QCOR 2012. Poster Presentation.


56. **63A**: Impact of Diabetes on Clinical Findings, Management, and In-Hospital Outcomes in Non-ST Elevation and ST Elevation Myocardial Infarction: An Analysis from the NCDR®. R. Pappy. AHA 2012 Poster Presentation.

February 2022


64. 48: Characteristics and Outcomes of Emergency Department Patients Treated with Thienopyridines: Results from the NCDR®. D. Diercks. AHA 2011. Oral Presentation.


66. 51B: Low Levels of High-Density Lipoprotein Cholesterol (HDL-C) at Presentation in Acute Coronary Syndromes (ACS) and its Relation to Angiographically-Observed Atherosclerotic Burden: Results from the NCDR®. Acharjee. AHA 2011. Poster Presentation.


74. 31: Differences in Practice Patterns and Outcomes between Hispanics and Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction: Results from ACTION Registry – Get with The Guidelines. L. Guzman. AHA QCOR 2010. Poster Presentation.


76. 34: Longer Hospital Length of Stay in Non-ST-Elevation Myocardial Infarction Associated with Higher Risk but Less Evidenced-Based Treatment: Results from ACTION Registry. R. Lopes. AHA QCOR. 2010 Poster Presentation.


85. 7: Timing of In-Hospital CABG in Relationship to Mortality for ACS Patients: Results from the NCDR ACTION Registry. J. de Lemos. ACC 2009. Oral Presentation.
86. 11A: Is Pre-Existing Coronary Disease a Risk Factor for In-Hospital Mortality? An Analysis from the NCDR ACTION-GWTG Registry. M. Kontos. ACC 2009 Poster Presentation.
94. 2: Decline in the Use of Drug-Eluting Stents for Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention - Results from the CRUSADE and ACTION Registries. M. Roe. ACC 2008.
95. 6: Short-term Outcomes of STEMI and NSTEMI in Patients with Chronic Kidney Disease: A Report from the National Cardiovascular Data ACTION Registry. C. Fox. ACC 2008.
98. 10: Early use of beta-blockers (BB) is a quality indicator for the treatment of patients (pts) with ST-segment elevation (STEMI) and non-ST-segment myocardial infarction (NSTEMI), despite limited randomized clinical trials data. However, data from the recent COMMIT trial found an early hazard with BBs in this setting, especially for pts with high-risk features. Kontos. ACC 2008.
February 2022

Diabetes Collaborative Registry®


2. **19:** Eligibility Varies Across the 3 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials Among Adults with Type 2 Diabetes: Implications from Analysis of the Diabetes Collaborative Registry. E. Wittbrodt. ACC 2018. Poster Presentation.


6. **N/A:** Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the LEADER Trial on Improving Cardiovascular Outcomes in Patients with Diabetes at High Cardiovascular Risk. S. Arnold. ACC 2017. Oral Presentation.

7. **N/A:** Describing the Cardio-Renal-Metabolic Patient within the Diabetes Collaborative Registry. LoCasale. ADA 2017. Oral Presentation.


11. **N/A:** Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the IRIS Trial on Improving Outcomes in Patients with Cerebrovascular Disease. S. Arnold. QCOR 2017. Poster Presentation.


13. **N/A:** Quality of care of the initial patient cohort of the Diabetes Collaborative Registry. S. Arnold. ADA 2016. Oral Presentation.

14. **N/A:** Defining the potential impact of the EMPA-REG OUTCOMES® trial on improving cardiovascular outcomes of patients in the Diabetes Collaborative Registry. Arnold. EASD 2016. Oral Presentation.
1. **248**: Outcomes of patients with recalled defibrillator leads: Results from the NCDR-ICD Registry. Zeitler. AHA 2020.
2. **151**: Longitudinal Outcomes After Implantation of a Subcutaneous or Transvenous ICD: A Report from the NCDR. Friedman. HRS 2020.
5. **184**: Use and Outcomes of Dual Chamber and CRT defibrillators among older patients undergoing ICD implantation with a ventricular pacing indication: An Analysis from the NCDR ICD Registry. R. Borne. ACC 2019.
7. **239**: Survival Following Implantable Cardioverter-Defibrillator Implantation in Patients with Cardiac Sarcoidosis. A. Annapureddy. ACC 2019.
8. **218**: Longitudinal Outcomes Associated with Non-Evidence-Based ICD Implantations Among Medicare Beneficiaries: A Report from the National Cardiovascular Data Registry. Daimee. AHA 2019.
15. **146**: Characteristics and Outcome of Pediatric Patients Who Undergo Placement of Implantable Cardioverter-Defibrillator - An Insight from the National Cardiovascular Data Registry (NCDR). Baskar. ACC 2018. Poster Presentation.
17. **107A**: Association Between Industry Payments and In-Hospital Procedure-Related Complication Rates Following ICD Implantation: Results from the NCDR ICD Registry. Henien. AHA 2018. Poster Presentation.
20. **185**: Defibrillation Safety Margin Testing in Congenital Heart Disease Patients with Implantable-Cardioverter Defibrillators: Results from the National Cardiovascular Data Registry ICD Registry. Prutkin. AHA 2018. Poster Presentation.


35. **79**: Comparative Effectiveness of Cardiac Resynchronization Therapy with Defibrillator versus Defibrillator Alone in Heart Failure Patients with Moderate to Severe Chronic Kidney Disease. D. Friedman. ACC 2015. Poster Presentation.


February 2022

41. **96**: Outcomes of Older Survivors of Sudden Cardiac Death Receiving Secondary Prevention Implantable Cardioverter Defibrillators - An Analysis from the NCDR ICD Registry. J. Betz. QCOR 2015. Never presented because conference was canceled.

42. **59B**: Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving Cardiac Resynchronization Therapy: Results from the NCDR®. R. Zusterzeel. ACC 2014. Poster Presentation.

43. **62A**: Non-trans venous Lead Implantation in Pediatric and Congenital Heart Disease Patients: Early Analysis from the NCDR-ICD Registry. C. Berul. ACC 2014. Poster Presentation.


45. **75**: Use and Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients with Heart Failure and Atrial Fibrillation: Data from the NCDR-ICD Registry. P. Khazanie. ACC 2014. Poster Presentation.

46. **59A**: Women have Better Survival than Men with Cardiac Resynchronization Therapy in Left Bundle Branch Block: An Observational Comparative Effectiveness Study from the National Cardiovascular Data Registry. R. Zusterzeel. AHA 2014. Oral Presentation.


50. **57C**: Cardiac Perforation from Implantable Cardioverter-Defibrillator Lead Placement and In-Hospital Adverse Events and Mortality: Insights from the NCDR®. J. Hsu. ACC 2013. Oral Presentation.


53. **52**: Clinical Effectiveness of Cardiac Resynchronization Therapy Compared to Medical Therapy Alone Among Patients with Heart Failure: An Analysis of the ICD and ADHERE National Registries. P. Khazanie. AHA 2013. Poster Presentation.


56. **71C**: Outcomes among Medicare beneficiaries are optimized when primary ICD implant occurs during an elective rather than unplanned hospitalization. G. Stewart. AHA 2013. Oral Presentation.


60. **57B**: Coronary Sinus Dissection from Cardiac Resynchronization Therapy Implantation and Associated In-Hospital Adverse Events: Insights from the NCDR®. J. Hsu. HRS 2013. Poster Presentation.

February 2022


63. 41: Low Body Mass Index is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J. Hsu. ACC 2012. Poster Presentation.


73. 41A: Low Body Mass Index is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J. Hsu. Bay Area Research Symposium 2011. Poster Presentation.


76. 5: The Relation between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation from the National Cardiovascular Data Registry. M. Hlatky. ACC 2010. Oral Presentation.

77. 24: Blood Pressure, BUN, Creatinine, Congestive Heart Failure and Cardiac Arrest (B2C3 Score) Predicts Procedure Mortality for Elective ICD Implantation: Data from the ICD Registry(TM). D. Haines. ACC 2010. Poster Presentation.

78. 35: Impact of the Medtronic Fidelis lead recall on utilization of implantable cardioverter defibrillators: Data from the NCDR ICD Registry. P. Bhatt. ACC 2010. Poster Presentation.


February 2022


84. **20B**: What is More Important in Cardiologists’ Decision Making Around Implantable Cardioverter Defibrillators (ICD), Mortality Data or Patient Preferences? D. Matlock. **QCOR 2010. Poster Presentation.**

85. **36**: Discretionary Use of Dual Lead Implantable Cardioverter-Defibrillators (ICDs) by Hospitals. D. Matlock. **QCOR 2010. Poster Presentation.**

86. **17**: Regional Variations of Primary Prevention Implantable Cardioverter-Defibrillators: Results from the National Cardiovascular Data Registry (NCDR). Matlock, Masoudi. **ACC 2009. Oral Presentation.**

87. **18**: Clinical Characteristics of Patients with End Stage Renal Disease on Dialysis Referred for Implantable Cardioverter Defibrillator Implantation. A. Aggarwal. **ACC 2009. Oral Presentation.**

88. **2**: Factors Influencing the Use of Higher-Tech/Higher Cost Implantable Cardioverter-Defibrillators: Data from the NCDR ICD Registry. R. Lampert. **AHA 2009. Poster Presentation.**

89. **22**: Prevalence and Predictors of "Off-label" use of Cardiac Resynchronization Therapy in Patients Enrolled in the NCDR ICD Registry. M. Reynolds. **AHA 2009. Poster Presentation.**


92. **31**: System Level Contributions to Disparities in Cardiac Resynchronization Therapy with Defibrillator in the ACC/NCDR ICD Registry. S. Farmer. **QCOR 2009.**


94. **7B**: Association of implanting physician certification with complications following implantable cardioverter-defibrillator procedures: Insights from the NCDR ICD Registry. J. Leubbert. **AHA 2008.**

95. **16**: Dual chamber ICD selection is associated with racial and socioeconomic disparities and increased complication rates among patients enrolled in the ACC-NCDR ICD Registry. T. Dewland. **AHA 2008.**

96. **1**: Racial and Ethnic Differences in Nationwide Utilization of Cardiac Resynchronization Therapy. S. A. Farmer. **AHA 2007.**

97. **3**: Differences in Implantation-Related Complications between Men and Women Receiving ICD Therapy for Primary Prevention. P. N. Peterson. **AHA 2007.**

98. **4**: Sex Differences in the Characteristics of Patients Receiving ICD Therapy for Primary Prevention. S. L. Daugherty. **AHA 2007.**


IMPACT Registry®

1. **24**: Risk of catastrophic outcome following cardiac catheterization for pulmonary hypertension: An analysis of data from the IMPACT® Registry. M. O’Byrne. **ACC 2017. Moderated Poster.**


3. **18B**: Variability in Practice Patterns and Consistency with Published Guidelines for Aortic and Pulmonary Balloon Valvuloplasty: An Analysis of Data from the IMPACT Registry. A. Glatz. **AHA 2016. Rapid Fire Moderated Poster.**

4. **5B**: Adjusting for Risk Associated with Congenital Cardiac Catheterization: A Report from the IMPACT® Registry. N. Jayaram. **CHOP 2016. Poster Presentation.**

5. **14**: Risk factors for adverse events after catheter-based procedures in adolescents and adults with congenital heart disease - a report from the IMPACT registry. A. Stefanescu. **ESC 2016. Poster Presentation.**


10. **1B**: The IMPACT Registry (Improving Pediatric and Adult Congenital Treatment): Update and Trends. R. Vincent. **ACC 2013. Poster Presentation.**

11. **3A**: First Review of Community Practice with respect to Aortic and Pulmonary Artery Stenting. J. Moore. **ACC 2013. Poster Presentation.**

12. **3B**: First Review of Community Practice with respect to Device Closure of ASD and PDA. J. Moore. **ACC 2013. Poster Presentation.**

13. **3C**: First Review of Community Practice with respect to Aortic and Pulmonary Valvuloplasty. J. Moore. **ACC 2013. Poster Presentation.**


15. **18C**: Improving Pediatric and Adult Congenital Treatment. J. Rome. **World Congress of Pediatric Cardiology & Cardiac Surgery (June 2009). Oral Presentation.**


February 2022

18. 29: Trainee Presence in the Cardiac Catheterization Laboratory and Association with Procedural Outcomes Following Pediatric Cardiac Catheterization. N. Jayaram CHOP. Poster Presentation.
1. **46: Gender Differences in Outcomes with Patients Undergoing Percutaneous Left Atrial Appendage Occlusion: Insights from the NCDR LAAO Registry.** D. Darden. *AHA 2020. Poster Presentation.*
1. **188**: Relationship Between Industry Payments to Physicians and Prescription Patterns for NOACs, PCSK9 inhibitors, and ARNI: A Report from the NCDR PINNACLE Registry. AHA 2020.
2. **198**: Association Between Cardiovascular Event Type and Smoking Cessation Rates Among Outpatients with Atherosclerotic Cardiovascular Disease: Insights from the NCDR PINNACLE Registry. AHA Epi Lifestyle 2020.
4. **180**: Relevance and Significance of Left Ventricular Ejection Fraction in Chronic Heart Failure Phenotypes in Patients with Heart Failure with Preserved, Midrange and Reduced Ejection Fraction: Results from the PINNACLE Registry. ACC 2019.
5. **218**: Baseline Assessment of the Current Management of Patients with ASCVD in the PINNACLE Registry. AHA 2019.
8. **172**: Advance Care Planning and Prognosis Education in Patients with Heart Failure: Insights from the NCDR PINNACLE Registry. AHA 2019.
14. **196**: The Benchmarking an Oral Anticoagulant Treatment Rate in Patients with Nonvalvular Atrial Fibrillation (BOAT-AF) study: A prospective, multicenter study evaluating perspectives on use of oral anticoagulation using a patient survey and clinical review by the treating physician among patients not currently treated with oral anticoagulation. AHA 2018.
15. **90**: Implications of the IMPROVE-IT Trial for Contemporary Cardiovascular Practice: An NCDR® Research to Practice (R2P) Project. T. Maddox. ACC 2017. Poster Presentation.

18. Implications of the LEGACY Trial of Weight Loss for Atrial Fibrillation in US Cardiovascular Practice: An NCDR PINNACLE Research to Practice (R2P) Project. **ACC 2017.**

19. **74**: Disparities and geographic variation in the treatment of atrial fibrillation in Native Americans enrolled in the ACC PINNACLE AF registry. **AHA 2017.**


22. **119**: Cardiovascular Secondary Prevention Therapies are Under prescribed in Patients with Peripheral Artery Disease: Findings from the NCDR PINNACLE Registry. **AHA 2017.**

23. **77**: Association of Insurance Type with Receipt of Oral Anticoagulation in Atrial Fibrillation: An Analysis of the American College of Cardiology NCDR PINNACLE Registry. C. Yong. **ACC 2016. Poster Presentation.**


31. **50**: The Relationship Between Provider Experience and Cardiac Performance Measure Compliance in Outpatients: Results from the NCDR. N. Thande. **ACC 2015. Poster Presentation.**


33. **61**: Factors Associated with Use of Newer Antiplatelet Agents in Patients Undergoing Drug Eluting Stent Placement: Analysis from The Pinnacle® Registry. S. Bandeali. **ACC 2015. Poster Presentation.**

34. **23C**: Development of a Nationwide Ambulatory Cardiovascular Registry: An Update on PINNACLE-AF. B. Mullen. **ACC 2014. Poster Presentation.**

35. **26**: Use of Novel Oral Anticoagulants for Patients with Non-Valvular Atrial Fibrillation: Results from the NCDR PINNACLE Registry. N. Shah. **ACC 2014. Poster Presentation.**

37. **60A**: Frequency and Practice Level Variation in Inappropriate and Non-Recommended Prasugrel Prescribing: Insights from the NCDR®PINNACLE Registry. R. Hira. ACC 2014. Young Investigator Award.


41. **60B**: Practice Variation in Antiplatelet and Anticoagulation Therapy for Patients with Both Atrial Fibrillation and Coronary Artery Disease. J. Wasfy. AHA 2014. Poster Presentation.


46. **43**: Differences in the Compliance of Coronary Artery Disease (CAD) Performance Metrics and Statin Use in Patients who have Undergone Recent Coronary Artery Bypass Grafting (CABG) Compared to Those with Recent Percutaneous Coronary Intervention (PCI). S. Bandeali. QCOR 2013. Poster Presentation.

47. **44**: Relationship of Provider and Practice Volume to Performance Measure Adherence for Patients with Coronary Disease. L. Fleming. QCOR 2013. Poster Presentation.


52. **23A**: Practice Level Variation in use of Recommended Medications among Outpatients with Heart Failure: A Report from the NCDR® PINNACLE Registry®. P. N. Peterson. QCOR 2012. Poster Presentation.
February 2022


64. **9B**: The American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program and Heart Failure Performance Measures: A Report of the first 14,000+ Patients. P. Chan. ACC 2010. Poster Presentation.

65. **N/A (IC3-10)**: Racial Differences in Outpatient Performance Measures: A Report of the first 10,000+ Patients in the American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program. P. Chan. ACC 2010. Poster Presentation.

66. **N/A (IC3-12)**: Outpatient Compliance with Performance Measures for Atrial Fibrillation: A Report of the first 14,000+ Patients from the American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program. P. Chan. ACC 2010. Oral Presentation.

67. **N/A (IC3-18)**: Feasibility of developing and implementing a national practice-based quality improvement program quality improvement: Results from the IC3 Program pilot. F. Fiocchi. Academy Health 2010. Poster Presentation.


70. **N/A (IC3-19)**: Building quality improvement from the ground up: Lessons from the design and implementation of the IC3 Program national practice-based quality improvement program. M. Elma.
February 2022


71. **N/A (IC3-20):** Implementing an Orientation and Training Program for Quality Improvement in the Office-based Setting: Initial Observations from the American College of Cardiology Improving Continuous Cardiac Care (IC3) Pilot Program Assessing the Feasibility of Implementing a Clinical Decision Support Tool in the Office-based Setting: Experiences from the American College of Cardiology’s Improving Continuous Cardiac Care (IC3) Pilot Program. K. Kehoe. QCOR 2010. Poster Presentation.


73. **N/A (IC3-22):** Utilization of a Clinical Registry to Drive Practice-Based Learning and Improvement among Cardiology Fellows in Training: Observations from the American College of Cardiology’s PINNACLE Registry. M. Frederick. QCOR 2010. Poster Presentation.

74. **N/A (IC3-13):** Building quality improvement from the ground up: Lessons from the design and implementation of the IC3 Program national practice-based quality improvement program. J. Wright. World Congress of Cardiology 2010. Oral Presentation.

75. **N/A (IC3-7):** The American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program: A Report of the first 10,000+ Patients. P. Chan. AHA 2009. Oral Presentation.

76. **N/A (IC3-8):** Electronic Medical Record Adoption in Cardiology Practices: A 2009 Snapshot from the American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program. K. Mitchell. AHA 2009. Poster Presentation.

77. **N/A (IC3-3):** The role of strategic alliances as a key success factor in the development of a national quality improvement program for office-based cardiology practices in the U.S. F. Fiocchi. QCOR 2009.

78. **N/A (IC3-4):** Claims versus Clinical Data Conundrum: Can Two Disparate Data Sources Measure Physician Performance for the Same Purpose in the Same Way: The PQRI Registry Alternative Perspective. P. Jones. QCOR 2009.

79. **N/A (IC3-5):** Challenges of Implementing Cardiac Performance Measures: Insights from the IC3 Program. J. Spertus. QCOR 2009.

80. **N/A (IC3-6):** Barriers and Facilitators to Implementing a Local Health Information Technology Initiative: Lessons Learned from a Local IC3 Program Pilot. K. Mitchell. QCOR 2009.
PVI Registry™


5. **422**: Patient-Reported Health Status Changes is Associated with Subsequent Clinical Outcomes After Transcatheter Valve Therapies: Insights from the STS/ACC TVT Registry. QCOR 2020.
6. **472**: Association of Cerebral Embolic Protection Devices with Transcatheter Aortic Valve Replacement Outcomes: Results from the STS/ACC TVT Registry. TCT Connect 2020.
8. **353**: Sex-Based Differences in Outcomes After Transcatheter Repair of Mitral Regurgitation with the Mitra Clip System. ACC 2019. Moderated Poster Presentation.
11. **371**: Learning curve for transcatheter mitral repair: Insights from the STS/ACC TVT Registry. TCT 2019. Late Breaking Clinical Trial Presentation.
February 2022


25. **285**: Change in Mitral Valve Gradient Following Mitra clip Repair and Correlation to 30-day and 1-year outcomes. V. Assche. TCT 2018.


February 2022


41. **106**: Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice. J. Carroll. ACC 2016. LBCT.

42. **133**: Transcatheter Aortic Valve Replacement is Associated with Fewer Hospital Days: A Report from the STS / ACC TVT Registry. S. Vemulapalli. ACC 2016.


44. **240**: Development of a Risk Prediction Model for 1-Year Mortality after Surgical vs. Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis. S. Baron. AHA 2016.


47. **33**: Incremental Value of Disease-Specific Health Status in Predicting Mortality after Transcatheter Aortic Valve Replacement. S. Arnold. ACC 2015. Poster Presentation.


49. **37**: Impact of Baseline Left Ventricular Function and Aortic Valve Gradient on Outcomes in Patients Treated with Transcatheter Aortic Valve Replacement: Results from the TVT Registry. S. Baron. ACC 2015. Oral Presentation.


51. **8**: One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry. D. Holmes. ACC 2014. Late-Breaking Clinical Trial: Oral Presentation.


February 2022


56. 44: Comparison of Alternative Access TAVR Techniques in the United States for Patients Considered High-Risk or Inoperable for Aortic Valve Replacement and with Severe Aortic Stenosis. V. Thourani. STS 2014. Oral Presentation.

57. 74: The Prognostic Impact of Chronic Lung Disease in 12,139 Patients Undergoing Transcatheter Aortic Valve Replacement: Results from the STS/ACC-TVT Registry. R. Suri. STS 2014. Oral Presentation.